Key result
Preoperative administration of levosimendan in CABG candidates with low LVEF and uncompensated heart failure significantly reduced the Vasoactive Inotropic Score at the end of surgery (median 5 vs 10, p=0.008) and shortened ICU and hospital stays.
Why the study?
To establish an approach to preoperative drug preparation for CAD patients with low LVEF and varying degrees of CHF compensation, and to study the possibility of using levosimendan in this preparation.
Does preoperative levosimendan improve early postoperative outcomes in patients with low LVEF and uncompensated heart failure undergoing CABG?
Observational (n=82)
No
Does preoperative levosimendan improve early postoperative outcomes in patients with low LVEF and uncompensated heart failure undergoing CABG?
Preoperative administration of levosimendan in CABG candidates with low LVEF and uncompensated heart failure improves early postoperative hemodynamics and reduces hospital stay.
May support preoperative levosimendan in high-risk CABG; leaves open confirmation by randomized trials before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gazizova et al. (2020) conducted an observational in Coronary artery disease with low left ventricular ejection fraction and chronic heart failure (n=82). Levosimendan vs. Standard therapy without levosimendan was evaluated on Vasoactive Inotropic Score (VIS) at the end of surgery (p=0.008). Preoperative administration of levosimendan in CABG candidates with low LVEF and uncompensated heart failure significantly reduced the Vasoactive Inotropic Score at the end of surgery (median 5 vs 10, p=0.008) and shortened ICU and hospital stays.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: